Compare NRG Energy Inc (NRG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs TG Therapeutics Inc — how do they compare? NRG Energy Inc trades at $132.3 (market cap $27.55B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: NRG Energy Inc is far larger — about 3.3× TG Therapeutics Inc's market cap, and NRG Energy Inc pays a 1.46% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NRG | TGTX | |
|---|---|---|
Market Cap | $27.55B | $8.26B |
Sector | Utilities | Health |
52-Week High | $184.03 | $59.06 |
52-Week Low | $120.65 | $26.39 |
Enterprise Value | $51.38B | $8.50B |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $131.60, up 1.93% over 24 hours, with a bearish technical signal despite bullish oscillators. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue grew to $30.71 billion in 2025, though net income margin remains thin at 0.74%. Analyst consensus is strongly bullish with a $217.50 price target, supported by institutional buying interest.
The outlook is cautiously optimistic given strong analyst support and strategic positioning for power demand growth, but risks include volatile cash flows, high debt levels, and execution challenges. The stock offers potential upside if earnings momentum improves, yet investors face headwinds from margin pressure and macroeconomic sensitivity.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
